List of Excipients in Branded Drug DAPTOMYCIN IN SODIUM CHLORIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Baxter Healthcare Corporation	DAPTOMYCIN IN SODIUM CHLORIDE	daptomycin in sodium chloride	0338-0712	SODIUM CHLORIDE
Baxter Healthcare Corporation	DAPTOMYCIN IN SODIUM CHLORIDE	daptomycin in sodium chloride	0338-0712	SODIUM PHOSPHATE, DIBASIC, ANHYDROUS
Baxter Healthcare Corporation	DAPTOMYCIN IN SODIUM CHLORIDE	daptomycin in sodium chloride	0338-0712	SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE
Baxter Healthcare Corporation	DAPTOMYCIN IN SODIUM CHLORIDE	daptomycin in sodium chloride	0338-0712	WATER

Daptomycin in Sodium Chloride: Excipient Strategy, Regulatory Position, and Commercial Opportunities

Last updated: September 5, 2026

Daptomycin in sodium chloride is a mature injectable anti-infective opportunity with limited active-ingredient differentiation. The strongest commercial positions are likely to come from ready-to-administer presentation, supply reliability, low waste, extended in-use stability, and hospital-pharmacy workflow advantages rather than new therapeutic claims.

Daptomycin is a cyclic lipopeptide antibiotic approved for complicated skin and skin-structure infections and Staphylococcus aureus bloodstream infections, including right-sided infective endocarditis in adults. It is administered intravenously and requires calcium for antibacterial activity. The reference product, Cubicin, is supplied as a sterile lyophilized powder that is reconstituted with 0.9% sodium chloride injection before administration.[1]

What is daptomycin in sodium chloride?

Daptomycin in sodium chloride generally refers to either a reconstituted daptomycin vial diluted in 0.9% sodium chloride or a ready-to-administer premixed intravenous product.

The formulation concept has two commercial forms:

Presentation	Typical use	Commercial advantage	Main limitation
Lyophilized daptomycin vial	Hospital reconstitution before infusion	Lower manufacturing complexity and broad channel acceptance	Pharmacy labor, preparation errors, vial waste
Daptomycin premixed in sodium chloride	Direct IV administration	Reduced compounding, faster administration, better standardization	Higher packaging and sterile-fill cost
Pharmacy bulk or institutional preparation	Centralized hospital or home-infusion use	Potentially lower unit cost	More complex compliance and stability controls
Ready-to-administer bag or flexible container	Inpatient, outpatient, and home infusion	Strong workflow and convenience proposition	Container compatibility and shelf-life burden

Daptomycin is not used for pneumonia because pulmonary surfactant inhibits its antibacterial activity.[1] The commercial opportunity therefore centers on bloodstream infection, endocarditis, complicated skin infections, outpatient parenteral antimicrobial therapy, and infections caused by resistant Gram-positive organisms.

Which excipients are used in daptomycin injectable products?

The reference lyophilized product uses a narrow excipient system. Daptomycin for injection is reconstituted with sterile 0.9% sodium chloride, and sodium hydroxide is used as a pH-adjusting agent in the vial formulation.[1]

The key excipient categories are:

Excipient or material	Function	Strategic relevance
Sodium chloride	Reconstitution and infusion vehicle; provides isotonicity	Core differentiator for compatibility, osmolality, and ready-to-use presentation
Sodium hydroxide	pH adjustment during drug-product manufacture	Controls solubility, degradation, and product consistency
Water for injection	Solvent in the manufacturing process or diluent system	Required for parenteral quality and low endotoxin control
Container and closure materials	Maintain sterility and chemical integrity	Critical for adsorption, extractables, leachables, and shelf life

A commercial premix may contain no pharmacologically active excipient beyond sodium chloride and may use a drug concentration selected to support a 50 mL or 100 mL infusion volume. This creates a relatively clean formulation profile for hospitals that seek to reduce exposure to preservatives, unnecessary buffers, and complex excipient systems.

The primary formulation challenge is not excipient count. It is maintaining daptomycin solubility, potency, low particulate levels, and acceptable stability after reconstitution and dilution.

Why is sodium chloride the preferred diluent for daptomycin?

Sodium chloride is commercially important because the approved product labeling identifies 0.9% sodium chloride injection as the reconstitution medium and supports administration in sodium chloride infusion solutions.[1]

The vehicle provides several advantages:

1. It is widely available in hospitals and home-infusion settings.
2. It has a familiar safety profile for intravenous administration.
3. It avoids the operational complexity of a specialty buffer system.
4. It supports standard pharmacy protocols.
5. It allows premixed products to align with existing IV administration practices.

Dextrose-containing solutions present a less attractive commercial pathway because the reference labeling identifies incompatibility concerns with dextrose-containing diluents.[1] A sodium-chloride-only strategy therefore reduces the risk of formulary restrictions and pharmacy substitution errors.

The formulation should be evaluated for pH, osmolality, concentration-dependent aggregation, visible and subvisible particles, container adsorption, and stability after temperature excursions. These factors are especially important for a cyclic lipopeptide administered at relatively high doses.

What formulation patents protect daptomycin products?

Daptomycin has a mature generic market and does not have the profile of a recently launched product protected primarily by new molecular entity exclusivity. The relevant intellectual-property issues are more likely to involve formulation, manufacturing, dosage regimen, packaging, and specific ready-to-administer presentations than basic active-ingredient exclusivity.

Potentially relevant patent categories include:

• Daptomycin compositions and salts
• Lyophilized injectable formulations
• pH-controlled formulations
• Reconstitution and dilution methods
• Stable liquid or premixed sodium chloride formulations
• Container-closure systems
• Manufacturing processes that control aggregation or impurities
• High-dose or extended-interval dosing methods
• Specific methods of treating bacteremia or endocarditis

The Orange Book is the principal source for patents listed against FDA-approved drug products, including reference daptomycin products and relevant generic approvals.[2] Patent analysis should distinguish between patents listed against the reference product and patents independently owned by a premix developer. A product may avoid an Orange Book-listed patent while still facing litigation risk from a formulation or process patent that is not listed in the same manner.

Because daptomycin was approved in 2003, the original composition and product patents are generally aged. The remaining commercial value is more likely to sit in narrow formulation claims, improved stability, container systems, or manufacturing know-how. Those rights may be difficult to enforce if the competing product uses a different concentration, packaging material, process sequence, or stability protocol.

When does daptomycin lose exclusivity?

Daptomycin’s original regulatory exclusivity has expired. The reference product was approved in 2003, and FDA-approved generic daptomycin products entered the U.S. market years later.[1,3]

The practical exclusivity position is therefore:

Exclusivity category	Current commercial relevance
New chemical entity exclusivity	Expired
Original reference-product market exclusivity	Expired
Basic active-ingredient patents	Largely aged or expired
Formulation patents	Product-specific; must be reviewed patent by patent
Method-of-use patents	Potentially relevant for narrow indications or dosing regimens
Regulatory exclusivity for generics	Generally unavailable as a durable barrier
Biosimilar exclusivity	Not applicable because daptomycin is a small-molecule antibiotic

The key distinction is between the absence of broad market exclusivity and the possible presence of narrower rights covering a specific premix or manufacturing approach.

Are Paragraph IV challenges relevant to daptomycin?

Paragraph IV litigation was more commercially relevant during the initial generic entry period. A generic applicant may certify that a listed patent is invalid, unenforceable, or not infringed, creating potential litigation under the Hatch-Waxman framework.[4]

For a current daptomycin-in-sodium-chloride strategy, Paragraph IV exposure depends on whether the proposed product is:

• An ordinary daptomycin-for-injection generic;
• A different concentration or infusion volume;
• A ready-to-administer sodium chloride premix;
• A product using a distinct container or manufacturing process;
• A product relying on a new stability profile or administration method.

A conventional generic vial has a lower patent differentiation profile but faces price competition. A premixed product may have more protectable technical features, but those features must be sufficiently specific and non-obvious to support durable patent claims.

What FDA regulatory pathway applies to daptomycin in sodium chloride?

A standard generic daptomycin injectable product is generally developed through an abbreviated new drug application, subject to pharmaceutical equivalence, bioequivalence requirements where applicable, and compliance with injectable-product quality standards.[3]

A premixed product may require a more complex regulatory strategy if it differs materially from the reference product in:

• Dosage form;
• Concentration;
• Container;
• Administration volume;
• Stability;
• Reconstitution status;
• Route or rate of administration;
• Labeling instructions.

The regulatory burden increases when the product is a ready-to-administer solution rather than a lyophilized powder requiring reconstitution. The sponsor must establish sterility assurance, container-closure integrity, particulate control, stability, extractables and leachables, and compatibility with administration sets.

FDA has also identified injectable drug shortages and manufacturing disruptions as important supply-chain concerns. A reliable domestic or diversified supply base can support hospital contracting even when the active ingredient itself is generic.[5]

What commercial opportunities exist for daptomycin premixes?

The strongest opportunity is workflow substitution. A premixed sodium chloride product can remove or reduce several hospital-pharmacy steps:

• Vial retrieval;
• Aseptic reconstitution;
• Dilution into an infusion bag;
• Label generation;
• Beyond-use dating management;
• Independent preparation checks;
• Disposal of partially used vials.

The product is particularly suited to:

Hospital inpatient therapy

Hospitals can use premixed units for standardized adult doses, especially where pharmacy workload and administration delays affect antimicrobial delivery.

Outpatient parenteral antimicrobial therapy

Home infusion providers value products with predictable storage, simple administration, and reduced preparation requirements. Premixed bags may reduce nursing time and lower the risk of home-compounding errors.

Long-term acute-care facilities

Long-term acute-care hospitals treat patients who may require extended courses for bacteremia, endocarditis, osteomyelitis, or complicated skin infections. A ready-to-administer product can reduce recurring preparation labor.

Antimicrobial stewardship programs

Standardized dose presentations can improve protocol compliance and reduce variation in preparation. The product still requires stewardship controls because daptomycin is a high-value agent commonly reserved for resistant Gram-positive infections.

Group purchasing and hospital contracts

A supplier can compete on total delivered cost rather than vial acquisition price. Relevant metrics include preparation time, discarded product, nursing labor, pharmacy labor, storage requirements, shortage performance, and medication-error risk.

How should dose presentation and sodium chloride volume be optimized?

Daptomycin dosing is weight-based and indication-specific. Adult regimens commonly use 4 mg/kg for complicated skin and skin-structure infections and 6 mg/kg for S. aureus bacteremia and right-sided endocarditis, with higher doses used in selected clinical practice settings.[1,6]

A practical presentation strategy may include:

Presentation concept	Potential use
350 mg in 50 mL	Smaller adult doses and pediatric weight-based dosing
500 mg in 50 mL	Common adult dosing and standardized inpatient use
500 mg in 100 mL	Lower concentration where infusion-volume flexibility is preferred
Multiple bag sizes	Weight-based dosing and reduced dose rounding
Pharmacy bulk format	High-volume institutional preparation

The commercial tradeoff is straightforward. Smaller volumes reduce fluid burden and shipping cost, while larger volumes may improve dose flexibility and concentration tolerance. Dose rounding should be aligned with institutional protocols and label requirements.

What manufacturing and IP barriers affect the opportunity?

The active ingredient is not the sole manufacturing constraint. The main barriers are sterile processing, lyophilization or aseptic liquid filling, impurity control, and stability.

Critical manufacturing controls include:

• Consistent daptomycin particle or solution characteristics;
• Tight pH control;
• Low bioburden and endotoxin levels;
• Control of aggregation and particulates;
• Validated sterilization or aseptic processing;
• Container-closure integrity;
• Resistance to adsorption and interaction with IV bags and tubing;
• Stability under refrigerated and room-temperature conditions.

A premix sponsor also needs a robust extractables and leachables program. Flexible polyolefin bags, multilayer films, ports, tubing, and overwraps can produce different chemical profiles from glass vials. The packaging system may become a technical barrier to entry, even when patent protection is weak.

How does daptomycin compare with competing anti-infective opportunities?

Daptomycin competes with vancomycin, linezolid, ceftaroline, and other agents used against resistant Gram-positive infections.

Product	Main commercial advantage	Main limitation
Daptomycin	Once-daily IV dosing and strong role in bacteremia	Not effective for pneumonia; creatine phosphokinase monitoring
Vancomycin	Broad hospital familiarity and low acquisition cost	Therapeutic drug monitoring and nephrotoxicity concerns
Linezolid	Oral and IV options	Hematologic and neurologic toxicity concerns with prolonged use
Ceftaroline	Broad anti-MRSA cephalosporin activity	More frequent dosing and higher formulation complexity
Daptomycin premix	Reduced preparation burden and outpatient suitability	Price pressure and limited indication scope

Daptomycin’s once-daily administration supports an outpatient value proposition that is less compelling for agents requiring frequent dosing or therapeutic drug monitoring.

What generic launch risks exist?

The principal risks are price erosion, contracting pressure, limited clinical differentiation, and technical failure in the ready-to-administer format.

A generic vial launch may achieve faster approval but face several competitors. A premixed product may command a higher price but must demonstrate enough savings in labor, waste, and administration time to justify formulary adoption.

Commercial risks include:

1. Hospital reluctance to pay a premium for a generic antibiotic.
2. Low utilization outside selected bloodstream and endocarditis cases.
3. Substitution by vancomycin or oral step-down therapy.
4. Manufacturing interruptions in sterile injectables.
5. Limited reimbursement recognition for convenience value.
6. Failure to obtain adequate dating for distribution and home infusion.
7. Contract loss if a competitor offers broader dose coverage.

What is the overall patent and commercial strength of daptomycin in sodium chloride?

The underlying daptomycin molecule has limited remaining exclusivity value. The commercial strength of a sodium chloride product depends on execution in four areas:

Factor	Assessment
Active-ingredient protection	Weak as a current barrier
Formulation differentiation	Moderate if stability, concentration, or presentation is meaningfully improved
Regulatory complexity	Moderate to high for a ready-to-administer sterile product
Commercial opportunity	Moderate, strongest in hospital and outpatient infusion channels
Pricing power	Limited for standard vials; higher for validated workflow savings
Supply-chain value	High when the product has reliable availability and extended dating

The most defensible strategy is a technically differentiated premix with validated compatibility, strong stability, and dose presentations aligned with hospital protocols. A conventional vial remains easier to register but offers less protection from commodity pricing.

Key Takeaways

• Daptomycin in sodium chloride is a mature generic injectable opportunity.
• Sodium chloride is the preferred commercial vehicle because it aligns with reference-product reconstitution and hospital practice.
• The strongest value proposition is ready-to-administer delivery, not a new active ingredient.
• The main excipient strategy is intentionally simple: sodium chloride for the vehicle and sodium hydroxide for pH adjustment.
• Formulation patents, container systems, stability claims, and manufacturing processes are more relevant than original molecule patents.
• A premix can reduce pharmacy labor, dose-preparation errors, vial waste, and administration delays.
• Hospital, home-infusion, and long-term acute-care channels offer the clearest commercial targets.
• Biosimilar competition is not relevant because daptomycin is a small-molecule drug.
• The key technical risks are aggregation, particulate formation, container compatibility, extractables and leachables, and sterile manufacturing reliability.
• Standard vials face substantial price erosion; premixed products require quantified workflow savings to support premium pricing.

FAQs

Is daptomycin in sodium chloride available as a ready-to-use infusion?

Some markets and suppliers offer premixed or pharmacy-prepared presentations, while the reference product is supplied as a lyophilized vial requiring reconstitution with 0.9% sodium chloride. Product-specific labeling controls storage, stability, and administration.

Can daptomycin be mixed with dextrose?

The reference labeling identifies incompatibility concerns with dextrose-containing diluents. Sodium chloride is the established vehicle for reconstitution and dilution.[1]

Does daptomycin require a preservative?

Daptomycin injectable products are generally designed as sterile, preservative-free parenteral products. Preservative selection would require a separate safety, compatibility, and regulatory assessment.

Is daptomycin a biosimilar product?

No. Daptomycin is a small-molecule antibiotic. Generic products are regulated through the abbreviated new drug application pathway rather than the biosimilar pathway.

What is the best commercial differentiator for a daptomycin premix?

The strongest differentiator is a validated ready-to-administer presentation with reliable stability, broad container compatibility, appropriate adult dose sizes, low waste, and documented reductions in pharmacy and nursing workload.

References

1. U.S. Food and Drug Administration. (2023). Cubicin (daptomycin for injection) prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2024). ANDA submissions: Generic drugs.
4. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417.
5. U.S. Food and Drug Administration. (2023). Drug shortages: Root causes and potential solutions.
6. Infectious Diseases Society of America. (2011). Clinical practice guidelines for the treatment of methicillin-resistant Staphylococcus aureus infections. Clinical Infectious Diseases, 52(3), e18-e55.